The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Loncastuximab tesirine receives EC approval for the treatment of adult patients with R/R DLBCL
On December 21, 2022, it was announced that loncastuximab tesirine, a CD19-targeted antibody–drug conjugate, received approval from the European Commission (EC) for the treatment of adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL); it marks a major clinical development for patients across Europe with DLBCL.1
This approval is based on key results from the phase II LOTIS-2 trial (NCT03589469), in which loncastuximab tesirine demonstrated durable responses in heavily pretreated patients with R/R DLBCL following ≥2 prior lines of systemic therapy.
Moreover, this follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in September. Prior to this, the U.S. Food and Drug Administration (FDA) granted its approval for this patient subset in April 2021.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
